Retatrutide Phase 3 Trials: TRIUMPH and TRANSCEND Research Guide

What are the retatrutide Phase 3 trials?

Retatrutide Phase 3 trials are Eli Lilly and Company's late-stage clinical programmes, TRIUMPH for obesity and TRANSCEND-T2D for type 2 diabetes, evaluating LY3437943, a 39-residue triple GLP-1, GIP and glucagon receptor agonist of roughly 4731 Da. TRIUMPH trials measure percent body-weight change, while TRANSCEND-T2D trials measure change in glycated haemoglobin (HbA1c).

Definition: Retatrutide (development code LY3437943;) is a synthetic, lipidated 39-residue peptide designed so that one molecule activates three receptors: the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon receptor (GCGR).

The significance of the Phase 3 stage is easiest to see against the two molecules that preceded retatrutide in the same pharmacological lineage. Semaglutide, from Novo Nordisk, activates GLP-1R alone. Tirzepatide, from the same sponsor as retatrutide, added GIPR agonism to GLP-1R agonism and became the first dual incretin agonist to reach the market.

Retatrutide adds a third arm, glucagon receptor agonism, which in rodent models raises energy expenditure rather than only suppressing intake. The Phase 3 programmes are the first large, randomised tests of whether that third arm changes outcomes at population scale, and they are also the first place where the long-term tolerability of chronic glucagon receptor activation will be characterised in thousands of participants rather than dozens.

Put plainly: Phase 3 is the final evidence stage before a sponsor files for approval, and retatrutide has reached it.

What is retatrutide at the molecular level?

Retatrutide is a 39-residue peptide with molecular formula C221H342N46O68, a molecular weight of approximately 4731 Da and CAS number 2381089-83-2.

Compound identity data — CAS number, molecular formula and molecular weight — is maintained on the Retatrutide reference page, which is the one page on this site that keeps it current.

Each non-canonical feature in the sequence answers a specific stability problem. Aib (alpha-aminoisobutyric acid) at position 2 blocks cleavage by dipeptidyl peptidase-4 (DPP-4), the enzyme that inactivates native GLP-1 and GIP within minutes of secretion. A second Aib at position 20 and the alpha-methyl-leucine at 13 constrain backbone conformation and reduce proteolytic susceptibility along the helical mid-region.

The C20 fatty diacid attached to Lys17 through a gamma-glutamate and AEEA spacer drives reversible binding to serum albumin, the same half-life extension strategy that tirzepatide uses, and the C-terminal amide removes a free carboxylate that exopeptidases would otherwise attack.

Together these substitutions convert a sequence whose native ancestors survive only minutes into one that persists for days in circulation.

In short, the modifications buy stability and albumin binding without abandoning receptor recognition.

How does retatrutide engage GLP-1, GIP and glucagon receptors?

Retatrutide is unbalanced by design: in the Coskun 2022 receptor pharmacology work it was roughly 8.9-fold more potent than native GIP at human GIPR, but only about 0.4-fold as potent as native GLP-1 at GLP-1R and about 0.3-fold as potent as native glucagon at GCGR.

The tilt toward GIPR and away from GCGR is deliberate. Glucagon receptor agonism raises hepatic glucose production, which would work against glycaemic control if it were not offset by the insulinotropic GLP-1R and GIPR arms. Keeping GCGR potency at roughly a third of native glucagon lets the molecule capture the energy-expenditure signal observed in diet-induced obese (DIO) mouse models while the incretin arms hold glucose in check.

In those DIO mouse experiments, Coskun and colleagues attributed a component of the weight reduction to increased energy expenditure associated with glucagon receptor engagement, a mechanism absent from GLP-1R mono-agonists such as semaglutide.

What remains uncharacterised matters as much. No published human study has partitioned retatrutide's clinical effects among the three receptors, and receptor occupancy in human liver, adipose or brain tissue has not been measured. The receptor-by-receptor picture comes from recombinant cell assays and rodents.

Plain-language version: the molecule leans hardest on GIP, uses glucagon lightly, and the human breakdown of who does what is still open.

Which Phase 3 programmes is retatrutide enrolled in?

Retatrutide Phase 3 trials fall into two named programmes: TRIUMPH, which studies obesity and overweight with and without specific comorbidities, and TRANSCEND-T2D, which studies type 2 diabetes.

The TRIUMPH programme is organised by comorbidity, so each trial asks a narrower question than a general weight-loss study:

• TRIUMPH-1: adults with obesity or overweight with weight-related conditions, the broad registration population.
• TRIUMPH-2: adults with obesity or overweight and type 2 diabetes.
• TRIUMPH-3: adults with obesity and established cardiovascular disease.
• TRIUMPH-4: adults with obesity and knee osteoarthritis, with knee pain added as an outcome.

TRANSCEND-T2D runs separately because diabetes registration hinges on HbA1c, not body weight. Splitting the programmes lets each set of trials be powered for its own primary endpoint.

One programme event deserves careful framing. Any sponsor topline announcement from the programme is a press release, not a peer-reviewed paper: it reports selected endpoints, omits full adverse-event tables and has not passed external review, so figures circulating from such announcements are treated here as preliminary rather than established. This guide does not reproduce them.

What earlier evidence supported moving retatrutide into Phase 3?

The foundational evidence is the 2022 Cell Metabolism discovery paper by Coskun and colleagues, which carried LY3437943 from receptor pharmacology through rodent studies to a first-in-human pharmacokinetic readout.

Coskun and colleagues titled their 2022 report on the molecule: “LY3437943, a Novel Triple Glucagon, GIP, and GLP-1 Receptor Agonist for Glycemic Control and Weight Loss: From Discovery to Clinical Proof of Concept.”

That paper supplied three things a sponsor needs before committing to multi-thousand-participant trials. It established the in-vitro potency profile summarised in the receptor table above. It showed body-weight reduction and improved glucose handling in DIO mice, with energy expenditure contributing to the effect.

And in a Phase 1 single-ascending-dose study in healthy participants it reported a terminal half-life of approximately 6 days. A half-life in that range places retatrutide alongside the other albumin-binding incretin analogues rather than short-acting analogues such as exenatide.

Phase 2 dose-ranging trials in obesity and in type 2 diabetes followed and informed Phase 3 dose selection. This guide restricts numeric efficacy statements to the discovery paper listed in its references.

So the path ran from cell assays, to mice, to a 6-day human half-life, to Phase 2, to TRIUMPH.

What is established, contested and unknown about retatrutide?

Retatrutide's receptor profile, molecular identity and approximately 6-day human half-life are established; Phase 3 efficacy magnitudes are provisional; long-term safety of chronic glucagon receptor activation is unknown.

What is established?

The 39-residue sequence, the 4731 Da mass, the CAS number 2381089-83-2 and the triple agonist mechanism are fixed identity facts. The relative potency values at GIPR, GLP-1R and GCGR come from recombinant human receptor assays reported in 2022, and the approximately 6-day half-life comes from a published Phase 1 study (Coskun 2022).

What is contested?

Headline weight-reduction percentages attributed to Phase 3 circulate widely on forums and in secondary coverage, often detached from trial name, dose arm, duration or analysis population (treatment-regimen versus efficacy estimand). Until full peer-reviewed Phase 3 manuscripts appear, any single percentage quoted without those four qualifiers is contested rather than established. The degree to which glucagon agonism, as opposed to the incretin arms, drives the clinical effect is also debated, because the rodent energy-expenditure signal has not been directly replicated with tissue-level measurement in humans.

What is unknown?

Three gaps stand out. Cardiovascular outcomes are unresolved: no retatrutide cardiovascular outcome trial has reported. No head-to-head Phase 3 comparison of retatrutide against tirzepatide or semaglutide has been published, so any side-by-side ranking of the three compares separate datasets, not a randomised contrast. And the lean-mass fraction of weight lost under triple agonism lacks a peer-reviewed Phase 3 figure.

Bottom line: the chemistry is settled, the clinical magnitudes are pending.

How should laboratories prepare retatrutide for in-vitro research?

Retatrutide is supplied to laboratories as a lyophilized powder and should be kept cold, dry and protected from light until reconstitution.

Lipidated peptides behave differently from short unmodified sequences. The C20 diacid side chain makes retatrutide amphiphilic, so it can adsorb to plastic and self-associate at high concentration, which distorts dose-response curves in cAMP accumulation or receptor-binding assays if handling is careless. The sequence below reflects standard practice for lipidated incretin analogues:

1. Store sealed lyophilized vials frozen, typically at -20 °C, and allow each vial to reach room temperature before opening to prevent condensation on the hygroscopic cake.
2. Record the lot number and match it against the batch Certificate of Analysis before any experiment.
3. Dissolve in an aqueous buffer appropriate to the assay, adding solvent down the vial wall and swirling gently rather than vortexing, because shear promotes aggregation of lipidated peptides.
4. Use low-binding tubes and pipette tips for serial dilutions, and include a carrier protein such as bovine serum albumin in assay buffer where the protocol allows, remembering that albumin will bind the fatty diacid and shift apparent potency.
5. Aliquot the reconstituted stock into single-use volumes and refreeze, avoiding repeated freeze-thaw cycles.
6. Run a native-ligand reference (GLP-1, GIP or glucagon) on the same plate so potency ratios can be compared with the published 0.4-fold, 8.9-fold and 0.3-fold values.

Serum albumin in buffer is not a neutral choice. It changes the free fraction of any C20-acylated peptide, which is one reason published potency values are always reported with assay conditions attached.

How does Peptide.Express verify research-grade retatrutide?

Peptide.Express sources retatrutide against a ≥99% HPLC purity specification and publishes Certificates of Analysis from an independent third-party laboratory for lots that have one on file.

A purity standard and a purity measurement are different things. The standard is the acceptance threshold a lot must clear; the measurement is the chromatographic figure reported for one specific batch, with identity confirmation where the laboratory reported it.

Researchers can check each lot's reported HPLC result on its Certificate of Analysis, listed on the third-party HPLC lab results and Certificates of Analysis page. For related incretin analogues and receptor-pharmacology primers, the in-depth compound research guides index collects our other entity-specific write-ups.

Third-party tested peptides matter most for multi-receptor ligands, because a truncated impurity can carry a different receptor bias than the parent sequence.

Research use only: Retatrutide sold by Peptide.Express is intended solely for in-vitro laboratory research by qualified professionals. It is not a drug, food or supplement, is not approved by the FDA for any use, and must not be administered to humans or animals. The clinical trials described in this guide are sponsor-run investigational studies and do not describe any use of research-grade material. For laboratory research use only. Not for human or veterinary use.

Retatrutide: References

• Coskun T, Urva S, Roell WC, et al. LY3437943, a Novel Triple Glucagon, GIP, and GLP-1 Receptor Agonist for Glycemic Control and Weight Loss: From Discovery to Clinical Proof of Concept. Cell Metabolism. 2022.
• ClinicalTrials.gov: TRIUMPH-1 NCT05929066; TRIUMPH-2 NCT05929079; TRIUMPH-3 NCT05882045; TRIUMPH-4 NCT05931367.